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Supplementary Note: 
Case control sample sets used in the study: 
Icelandic study population.  Records of all urinary bladder cancer diagnoses were obtained from 
the Icelandic Cancer Registry (ICR) (http://www.krabbameinsskra.is).  The ICR contains all 
cancer diagnoses in Iceland from January 1, 1955. The ICR contained records of 1,777 Icelandic 
UBC patients diagnosed until December 31, 2008, and all prevalent cases were eligible to 
participate.  The participation rate for newly diagnosed cases was 65%.  Patients were recruited 
by trained nurses on behalf of the patients’ treating physicians, through special recruitment 
clinics.  Participants in the study donated a blood sample and answered a lifestyle questionnaire.  
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A total of 611 patients (76% males; diagnosed from December 1974 to December 2008) were 
included in a genome-wide SNP genotyping effort, using the Infinium II assay method and either 
the Sentrix HumanHap 300 or HumanCNV370-duo BeadChip (Illumina).  The median age at 
diagnosis for all consenting cases was 68 years (range 22-95 years) as compared to 68.5 years for 
all UBC patients in the ICR.  The 37,478 controls (41% males; mean age 61 years; SD = 21) used 
in this study consisted of individuals from other ongoing genome-wide association studies at 
deCODE and represent over 15% of the adult population of Iceland.  No individual disease group 
is represented by more than 10% of the total control group.  Cancer patients (prostate, breast, 
colorectal and lung) were analyzed separately, and the frequency of the sequence variants studied 
did not differ from other controls.  Samples from prostate, breast, colorectal and lung cancer 
patients as well as individuals used for the analysis of smoking variables come from other 
ongoing project at deCODE Genetics.  The study was approved by the Data Protection Authority 
of Iceland and the National Bioethics Committee.  Written informed consent was obtained from 
all patients, relatives and controls.  Personal identifiers associated with medical information and 
blood samples were encrypted with a third-party encryption system in which the Data Protection 
Authority maintains the code.  
 
Dutch population 
Two groups from the Netherlands were included in this study, the discovery population which 
was genotyped by chip and group 2 which was used for replication. 
The Netherlands, discovery population.  The Dutch patients were recruited for the Nijmegen 
Bladder Cancer Study (see http://dceg.cancer.gov/icbc/membership.html). The Nijmegen Bladder 
Cancer Study identified patients through the population-based regional cancer registry held by 
the Comprehensive Cancer Centre East, Nijmegen that serves a region of 1.3 million inhabitants 
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in the eastern part of the Netherlands (www.ikcnet.nl).  Patients diagnosed between 1995 and 
2006 under the age of 75 years were selected and their vital status and current addresses updated 
through the hospital information systems of the 7 community hospitals and one university 
hospital (Radboud University Nijmegen Medical Centre, RUNMC) that are covered by the cancer 
registry.  All patients still alive on August 1, 2007 were invited to the study by the 
Comprehensive Cancer Center on behalf of the patients’ treating physicians.  In case of consent, 
patients were sent a lifestyle questionnaire to fill out and blood samples were collected by 
Thrombosis Service centers which hold offices in all the communities in the region.  1,651 
patients were invited to participate.  Of all the invitees, 1,082 gave informed consent (66%): 992 
filled out the questionnaire (60%) and 1016 (62%) provided a blood sample.  The number of 
participating patients was increased with a non-overlapping series of 376 bladder cancer patients 
who were recruited previously for a study on gene-environment interactions in three hospitals 
(RUNMC, Canisius Wilhelmina Hospital, Nijmegen, and Streekziekenhuis Midden-Twente, 
Hengelo, the Netherlands).  Ultimately, completed questionnaires and blood samples were 
available for 1,276 and 1,392 patients, respectively.  All the patients that were selected for the 
analyses (N=1,278) were of self-reported European descent.  The median age at diagnosis was 62 
(range 25-93) years.  82% of the participants were males.  Data on tumor stage and grade were 
obtained through the cancer registry.  The 1,832 control individuals (46% males) were cancer 
free and frequency-matched for age with the cases.  They were recruited within a project entitled 
“Nijmegen Biomedical Study”.  The details of this study were reported previously 1.  Briefly, this 
is a population-based survey conducted by the Department of Epidemiology and Biostatistics and 
the Department of Clinical Chemistry of the Radboud University Nijmegen Medical Centre 
(RUNMC), in which 9,371 individuals participated from a total of 22,500 age and sex stratified, 
randomly selected inhabitants of Nijmegen.  Control individuals from the Nijmegen Biomedical 
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Study were invited to participate in a study on gene-environment interactions in multifactorial 
diseases such as cancer.  All the 1,832 participants in the present study are of self-reported 
European descent and were fully informed about the goals and the procedures of the study. The 
study protocols of the Nijmegen Bladder Cancer Study and the Nijmegen Biomedical Study were 
approved by the Institutional Review Board of the RUNMC and all study subjects gave written 
informed consent. 
The Netherlands, group 2.  The second group of Dutch cases (Netherlands group 2) consisted of 
334 individuals from the Nijmegen Bladder Cancer Study who were diagnosed after 2006 and 
had not been genotyped by chip. The distributions of age at diagnosis and gender and response 
rates were comparable to those of the discovery group.  Controls for group 2 consisted of samples 
that had been chip genotyped in conjunction with other studies and have been described in a 
previous publication2.  Briefly, these controls were recruited from 3 sources; 1) 450 control 
individuals were unrelated, healthy volunteers who accompanied non-ALS patients to the UMC 
Utrecht neurology outpatient clinic, 2) 603 controls were recruited from an ongoing, prospective 
population-based study on ALS in The Netherlands and 3) 677 control individuals were included 
from a genome-wide association study on schizophrenia3.  The controls were volunteers and were 
free of any psychiatric history.  All were of Dutch descent, with at least three out of four 
grandparents of Dutch ancestry. 
 
Leeds Bladder Cancer Study, United Kingdom.  Details of the Leeds Bladder Cancer Study have 
been reported previously4.  In brief, patients from the urology department of St James’s 
University Hospital, Leeds were recruited from August 2002 to March 2006.  All those patients 
attending for cystoscopy or transurethral resection of a bladder tumor (TURBT) who had 
previously been found, or were subsequently shown, to have urothelial cell carcinoma of the 
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bladder were included.  Exclusion criteria were significant mental impairment or a blood 
transfusion in the past month.  All non-Caucasians were excluded from the study leaving 764 
patients.   The median age at diagnosis of the patients was 73 years (range 30-101).  71% of the 
patients were male and 36% of all the patients had a low risk tumor (pTaG1/2).  The controls 
were recruited from the otolaryngology outpatients and ophthalmology inpatient and outpatient 
departments at St James’s Hospital, Leeds, from August 2002 to March 2006.  All controls of 
appropriate age for frequency matching with the cases were approached and recruited if they 
gave their informed consent.  As for the cases, exclusion criteria for the controls were significant 
mental impairment or a blood transfusion in the past month.  Also, controls were excluded if they 
had symptoms suggestive of bladder cancer, such as haematuria.  2.8% of the controls were non-
Caucasian leaving 530 Caucasian controls for the study.  71% of the controls were male.  Data 
were collected by a health questionnaire on smoking habits and smoking history (non- ex- or 
current smoker, smoking dose in pack-years), occupational exposure history (to plastics, rubber, 
laboratories, printing, dyes and paints, diesel fumes), family history of bladder cancer, ethnicity 
and place of birth, and places of birth of parents.  The response rate of cases was approximately 
99%, that among the controls approximately 80%.  Ethical approval for the study was obtained 
from Leeds (East) Local Research Ethics Committee, project number 02/192. 
 
Torino Bladder Cancer Case Control Study, Italy. The source of cases for the Torino bladder 
cancer study are two urology departments of the main hospital in Torino, the San Giovanni 
Battista Hospital 5.  Cases are all Caucasian men, aged 40 to 75 years (median 63 years) and 
living in the Torino metropolitan area.  They were newly diagnosed between 1994 and 2006 with 
a histologically confirmed, invasive or in situ, bladder cancer.  Of all the patients with 
information on stage and grade, 56% were low risk (pTaG1/2).  The sources of controls are 
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urology, medical and surgical departments of the same hospital in Torino.  All controls are 
Caucasian men resident in the Torino metropolitan area.  They were diagnosed and treated 
between 1994 and 2006 for benign diseases (such as prostatic hyperplasia, cystitis, hernias, heart 
failure, asthma, and benign ear diseases).  Controls with cancer, liver or renal diseases and 
smoking related conditions were excluded.  The median age of the controls was 57 years (range 
40 to 74).  Data were collected by a professional interviewer who used a structured questionnaire 
to interview both cases and controls face-to-face.  Data collected included demographics (age, 
sex, ethnicity, region and education) and smoking.  For cases, additional data were collected on 
tumor histology, tumor site, size, stage, grade, and treatment of the primary tumor.  The response 
rates were 90% for cases and 75% for controls resulting in 328 cases and 389 controls.  Ethical 
approval for the study was obtained from Comitato Etico Interaziendale, A.O.U. San Giovanni 
Batista – A.). C.T.O./ Maria Adelaide.  
 
The Brescia bladder cancer study, Italy. The Brescia bladder cancer study is a hospital-based 
case-control study. The study was reported in detail previously6.  In short, the catchment area of 
the cases and controls was the Province of Brescia, a highly industrialized area in Northern Italy 
(mainly metal and mechanical industry, construction, transport, textiles) but also with relevant 
agricultural areas.  Cases and controls were enrolled in 1997 to 2000 from the two main city 
hospitals.  The total number of eligible subjects was 216 cases and 220 controls.  The response 
rate (enrolled/eligible) was 93% (N=201) for cases and 97% (N=214) for controls.  Only males 
were included.  All cases and controls had Italian nationality and were of Caucasian ethnicity.  
All cases had to be residents of the Province of Brescia, aged between 20 and 80, and newly 
diagnosed with histologically confirmed bladder cancer.  The median age of the patients was 63 
years (range 22-80). 29% of all the patients with known stage and grade had a low risk tumor 
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(pTaG1/2).  Controls were patients admitted for various urological non-neoplastic diseases and 
were frequency matched to cases on age, hospital and period of admission.  The study was 
formally approved by the ethical committee of the hospital where the majority of subjects were 
recruited.  A written informed consent was obtained from all participants.  Data were collected 
from clinical charts (tumor histology, site, grade, stage, treatments, etc.) and by means of face-to-
face interviews during hospital admission, using a standardized semi-structured questionnaire.  
The questionnaire included data on demographics (age, ethnicity, region, education, residence, 
etc.), and smoking. ISCO and ISIC codes and expert assessments were used for occupational 
coding.  Blood samples were collected from cases and controls for genotyping and DNA adducts 
analyses.    
 
The Belgian Case Control Study of Bladder Cancer. The Belgian study has been reported in 
detail7.  In brief, cases were selected from the Limburg Cancer Registry (LIKAR) and were 
approached through urologists and general practitioners.  All cases were diagnosed with 
histologically confirmed urothelial cell carcinoma of the bladder between 1999 and 2004, and 
were Caucasian inhabitants of the Belgian province of Limburg.  The median age of the patients 
was 68 years. 86% of all the patients were males.  For the recruitment of controls, a request was 
made to the “Kruispuntbank” of the social security for simple random sampling, stratified by 
municipality and socio-economic status, among all citizens above 50 years of age of the province.  
The median age of the controls was 64 years; 59% of the controls were males.  Three trained 
interviewers visited cases and controls at home.  Information was collected through a structured 
interview and a standardized food frequency questionnaire.  In addition, biological samples were 
collected. Data collected included medical history, lifetime smoking history, family history of 
bladder cancer and a lifetime occupational history.  Informed consent was obtained from all 
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participants and the study was approved by the ethical review board of the Medical School of the 
Catholic University of Leuven, Belgium.  
 
The Eastern Europe study population. The details of this study have been described previously8.  
Cases and controls were recruited as part of a study designed to evaluate the risk of various 
cancers due to environmental arsenic exposure in Hungary, Romania and Slovakia between 2002 
and 2004.  The recruitment was carried out in the counties of Bacs, Bekes, Csongrad and Jasz-
Nagykun-Szolnok in Hungary; Bihor and Arad in Romania; and Banska Bystrica and Nitra in 
Slovakia.  The cases (N=214) and controls (N=533) selected were of Hungarian, Romanian and 
Slovak nationalities.  Bladder cancer patients were invited on the basis of histopathological 
examinations by pathologists.  Hospital-based controls were included in the study, subject to 
fulfillment of a set of criteria.  All general hospitals in the study areas were involved in the 
process of control recruitment.  The controls were frequency matched with cases for age, gender, 
country of residence and ethnicity.  Controls included general surgery, orthopedic and trauma 
patients aged 30–79 years.  Patients with malignant tumors, diabetes and cardiovascular diseases 
were excluded as controls.  The median age for the bladder cancer patients was 65 years (range 
36-90).  83% of the patients were males.  The median age for the controls was 61 years (range 
28-83). 51% of the controls were males.  The response rates among cases and controls were 
~70%.  Of all the patients with known stage and grade information, 28% had a low risk tumor 
(pTaG1/2).  Clinicians took venous blood and other biological samples from cases and controls 
after consent forms had been signed.  Cases and controls recruited to the study were interviewed 
by trained personnel and completed a general lifestyle questionnaire.  Ethnic background for 
cases and controls was recorded along with other characteristics of the study population.  Local 
ethical boards approved the study plan and design.  
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 The Swedish Bladder Cancer Study.  The Swedish patients come from a population-based study 
of urinary bladder cancer patients diagnosed in the Stockholm region in 1995-19969.  Blood 
samples from 352 patients were available out of a collection of 538 patients with primary 
urothelial carcinoma of the bladder.  The average age at onset for these patients is 69 years (range 
32-97 years) and 67% of the patients are males.  Clinical data, including age at onset, grade and 
stage of tumor, were prospectively obtained from hospitals and urology units in the region.  The 
control samples came from blood donors in the Stockholm region and were from cancer free 
individuals of both genders.  The regional ethical committee approved of the study and all 
participants gave informed consent. 
 
The Spanish bladder cancer sample set. The Spanish study patients were recruited from the 
Urology and Oncology Departments of Zaragoza Hospital between September 2007 and June 
2009.  246 patients with histologically-proven urothelial cell carcinoma of the bladder were 
enrolled (response 77%).  Clinical information including age at onset, grade and stage was 
obtained from medical records.  The median age at diagnosis for the patients was 65 years (range 
27 to 94) and 87% were males.  The 890 Spanish control individuals were part of a larger 
collection of control samples obtained from individuals that had attended the University Hospital 
in Zaragoza, Spain, for diseases other than cancer between November 2001 and May 2007.  The 
controls were of both genders and median age was 52 years (range 11-87).  Controls were 
questioned to rule out prior cancers before drawing the blood sample.  All patients and controls 
were of self-reported European descent.  Study protocols were approved by the Institutional 
Review Board of Zaragoza University Hospital.  All subjects gave written informed consent. 
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Lutherstadt Wittenberg bladder cancer study, Germany. 
Details of the bladder cancer cases of this study have been reported previously10,11.  In brief, 221 
patients with a confirmed bladder cancer from the Department of Urology, Paul Gerhardt 
Foundation, Lutherstadt Wittenberg, Germany, were included.  Patients were enrolled from 
December 1995 to January 1999.  Exclusion criterion was a missing written informed consent 
into the study.  The median age of the patients was 65 years (range 20-91); 86% of the patients 
were males.  A total of 214 controls were from the same department of urology, but were 
admitted for treatment of benign urological diseases.  Exclusion criteria were malignant disease 
in the medical history or a missing written informed consent.  The median age of the controls was 
68 years (range 29-91); 84% of the controls were males.  Data were collected from July 2000 to 
May 2005.  All cases and controls were Caucasians, which was confirmed by questionnaire-based 
documentation of nationality.  Cases and controls were matched for age.  Data collected in cases 
and controls include age, gender, a complete documentation of occupational activities performed 
at least for 6 months, documentation of work places with known bladder cancer risk over the 
entire working life, exposures to known or suspected occupational bladder carcinogens, lifetime 
smoking habits, family history of bladder cancer, numbers of urinary infections treated by drugs 
during the previous 10 years, place of birth and places of residency for more than 10 years.  For 
bladder cancer cases, data on tumor staging, grading and treatment were taken from the records.  
First diagnosis of bladder cancer was recorded from July 1979 to January 1999. The local ethics 
committee approved the study plan and design. 
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SUPPLEMENTARY TABLES 
 
 
Chrom. Position SNP Allele OR P Cases Freq Controls Freq OR P Cases Freq Controls Freq OR CI 95 P Pheta I2 b Prev. Rep.c
2 84,927,324 rs2162567 A 1.19 6.6E-03 1,277 0.22 1,832 0.20 1.28 4.6E-04 611 0.24 37,468 0.20 1.23 (1.12,1.35) 1.3E-05 0.42 0 n
3 191,079,549 rs1515490 T 1.17 1.2E-02 1,276 0.79 1,832 0.76 1.34 1.0E-04 611 0.83 37,455 0.78 1.23 (1.12,1.35) 1.0E-05 0.16 50 n
3 191,128,627 rs710521 A 1.24 3.0E-04 1,277 0.76 1,832 0.72 1.24 1.5E-03 611 0.76 37,466 0.72 1.24 (1.13,1.35) 1.5E-06 0.99 0 y
4 1,704,037 rs798766 T 1.19 4.8E-03 1,277 0.23 1,832 0.20 1.26 1.4E-03 611 0.22 37,478 0.18 1.22 (1.11,1.34) 2.4E-05 0.56 0 n
4 175,588,362 rs7664475 A 1.15 5.6E-03 1,278 0.47 1,832 0.43 1.21 1.2E-03 610 0.57 37,423 0.52 1.18 (1.09,1.27) 2.5E-05 0.53 0 n
5 82,115,972 rs1549262 A 1.15 3.4E-02 1,273 0.22 1,822 0.19 1.36 6.4E-06 602 0.28 37,064 0.22 1.24 (1.13,1.36) 3.4E-06 0.069 70 n
6 26,249,354 rs806970 T 1.33 6.7E-03 1,278 0.07 1,832 0.06 1.40 9.4E-04 610 0.10 37,471 0.07 1.37 (1.18,1.58) 2.1E-05 0.7 0 n
7 131,715,919 rs10240737 A 1.37 7.4E-05 1,278 0.90 1,832 0.86 1.20 7.4E-02 608 0.91 37,209 0.89 1.30 (1.15,1.47) 2.5E-05 0.28 13 y
8 128,787,250 rs9642880 T 1.22 1.5E-04 1,269 0.53 1,824 0.48 1.23 4.6E-04 604 0.53 37,329 0.48 1.22 (1.13,1.32) 2.5E-07 0.88 0 y
9 21,747,803 rs1335510 G 1.25 1.8E-05 1,277 0.47 1,832 0.42 1.15 2.0E-02 611 0.50 37,367 0.47 1.20 (1.11,1.30) 2.0E-06 0.28 16 n
9 21,761,241 rs1341866 G 1.24 2.6E-05 1,278 0.47 1,832 0.42 1.14 2.7E-02 611 0.50 37,477 0.46 1.20 (1.11,1.29) 3.8E-06 0.27 19 n
9 21,796,564 rs10757257 A 1.24 4.3E-05 1,278 0.47 1,831 0.41 1.13 3.6E-02 610 0.49 37,480 0.46 1.19 (1.10,1.28) 8.4E-06 0.26 22 n
10 80,536,170 rs1092116 C 1.29 2.6E-03 1,275 0.91 1,832 0.88 1.34 1.4E-03 611 0.89 37,454 0.86 1.31 (1.16,1.48) 1.2E-05 0.74 0 y
12 111,515,857 rs233722 T 1.21 2.3E-04 1,277 0.63 1,830 0.58 1.23 1.3E-03 610 0.73 37,443 0.69 1.22 (1.13,1.32) 1.0E-06 0.85 0 y
12 111,524,326 rs233716 A 1.21 3.3E-04 1,277 0.63 1,828 0.58 1.24 1.2E-03 610 0.73 37,417 0.68 1.22 (1.13,1.32) 1.4E-06 0.79 0 y
13 85,735,283 rs12584999 A 1.18 8.7E-03 1,277 0.24 1,832 0.21 1.29 3.0E-04 610 0.25 37,469 0.20 1.22 (1.12,1.34) 1.3E-05 0.33 0 y
17 16,468,520 rs8065506 C 1.17 5.0E-03 1,277 0.73 1,829 0.70 1.27 8.5E-04 608 0.80 37,315 0.76 1.21 (1.11,1.32) 1.9E-05 0.39 0 n
18 41,570,268 rs692899 G 1.16 5.7E-03 1,278 0.40 1,832 0.36 1.23 7.6E-04 609 0.38 37,440 0.33 1.19 (1.10,1.29) 1.8E-05 0.46 0 n
19 40,960,311 rs12982672 G 1.34 5.9E-04 1,277 0.91 1,831 0.88 1.28 1.1E-02 608 0.90 37,291 0.88 1.31 (1.16,1.49) 2.1E-05 0.72 0 y
X 56,444,998 rs5913935 G 1.37 2.6E-05 1,278 0.16 1,831 0.12 1.23 4.9E-02 611 0.12 37,449 0.10 1.32 (1.17,1.48) 5.1E-06 0.39 0 n
c
Prev. Rep. Indicates whether the markers had been a part of a previous replication effort described in Kiemeney et al. 2008
b
I
2
 takes values between 0% and 100% and describes the proportion of the total variation in estimates that is due to heterogeneity 
Supplementary table 1 - Top 20 markers from Genome wide association analysis of bladder cancer in the Netherlands and Iceland. 
The Netherlands discovery group Iceland Combined
a
Phet denotes the tests of heterogeneity performed by comparing the null hypothesis of the effect being the same in all populations to the alternative hypothesis of each population 
having a different effect using a likelihood ratio test.  
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 Average age 
at diagnosis
(range)
Discovery groups (GWA)
Iceland 611 37,478 68 (20-95) 76 Population based
The Netherlands, discovery group 1,278 1,832 62 (25-93) 81 Population based
Follow up groups
UK, Leeds 771 574 73 (30-101 ) 71 Hospital-based
Italy, Torino 332 391 63 (40-75) 100 Hospital-based
Italy, Brescia 183 193 63 (22-80) 100 Hospital-based
Belgium, Leuven 201 385 68 (40-93 ) 86 Population based
Eastern Europe                           
(Hungary, Romania, Slovakia) 214 533 65 (36-90) 83 Hospital-based
Sweden, Stockholm 352 1,350 69 (32-97) 67 Population based
Spain, Zaragoza 246 890 65 (27-94) 87 Hospital-based
Germany, Lutherstadt Wittenberg 217 202 65 (20-91) 86 Hospital-based
The Netherlands, group 2 334 1,721 64 (30-91) 83 Population-based
Total 4,739 45,549
Supplementary table 2. Case control groups used in the study
Study Group #cases #controls
% males 
(cases)
Study type
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Chrom. Position SNP Allele OR 95% CI P Pheta I2 b Cases Freq Controls Freq Centers OR CI 95 Pc Pheta I2 b
2 84,927,324 rs2162567 A 1.02 (0.93,1.13) 0.66 0.71 0 2,170 0.19 3,616 0.19 7 1.13 (1.05,1.21) 0.0005 0.18 30
3 191,079,549 rs1515490 T 1.11 (1.01,1.23) 0.033 0.044 54 2,121 0.79 3,640 0.78 7 1.17 (1.10,1.26) 3.2×10
-6
0.028 54
3 191,128,627 rs710521 A 1.14 (1.04,1.25) 0.005 0.52 0 2,128 0.76 3,837 0.73 7 1.19 (1.12,1.27) 6.1×10
-8
0.55 0
4 1,704,037 rs798766 T 1.26 (1.16,1.37) 8.5×10
-8
0.47 0 2,691 0.23 5,959 0.19 9 1.24 (1.17,1.32) 9.9×10
-12
0.62 0
4 175,588,362 rs7664475 A 0.93 (0.85,1.03) 0.15 0.55 0 1,623 0.47 1,955 0.50 5 1.08 (1.01,1.14) 0.017 0.0072 66
5 82,115,972 rs1549262 A 0.93 (0.83,1.05) 0.25 0.43 0 1,594 0.18 1,998 0.19 5 1.12 (1.04,1.20) 0.0024 0.002 71
6 26,249,354 rs806970 T 1.00 (0.85,1.17) 0.96 0.1 43 2,169 0.07 3,627 0.07 7 1.18 (1.06,1.32) 0.0018 0.014 58
7 131,715,919 rs10240737 A 0.96 (0.85,1.08) 0.5 1 0 2,128 0.88 3,818 0.89 7 1.11 (1.02,1.21) 0.014 0.082 43
8 128,787,250 rs9642880 T 1.20 (1.11,1.30) 5.7×10
-6
0.36 9 2,091 0.49 3,780 0.44 7 1.21 (1.15,1.28) 6.7×10
-12
0.57 0
9 21,747,803 rs1335510 G 1.04 (0.96,1.12) 0.38 0.92 0 2,386 0.41 2,919 0.41 8 1.12 (1.06,1.12) 5.5×10
-5
0.28 18
9 21,761,241 rs1341866 G 1.04 (0.96,1.12) 0.34 0.89 0 2,401 0.41 2,938 0.41 8 1.12 (1.06,1.12) 6.9×10
-5
0.31 15
9 21,796,564 rs10757257 A 1.05 (0.95,1.16) 0.33 0.91 0 1,591 0.40 2,021 0.39 5 1.13 (1.07,1.20) 4.0×10
-5
0.4 4
10 80,536,170 rs1092116 C 0.98 (0.87,1.11) 0.81 0.52 0 2,105 0.88 3,780 0.89 7 1.14 (1.05,1.24) 0.0031 0.045 49
12 111,515,857 rs233722 T 0.97 (0.89,1.05) 0.4 0.15 37 1,994 0.57 3,822 0.59 7 1.09 (1.03,1.15) 0.0035 0.0012 69
12 111,524,326 rs233716 A 0.96 (0.89,1.04) 0.35 0.39 5 2,135 0.57 3,847 0.59 7 1.08 (1.02,1.15) 0.0062 0.0032 65
13 85,735,283 rs12584999 A 0.99 (0.90,1.10) 0.87 0.98 0 2,018 0.20 3,768 0.21 7 1.11 (1.04,1.19) 0.0017 0.19 29
17 16,468,520 rs8065506 C 0.99 (0.90,1.09) 0.86 0.11 41 2,064 0.73 2,994 0.74 7 1.10 (1.03,1.18) 0.0027 0.0092 61
18 41,570,268 rs692899 G 1.03 (0.93,1.14) 0.54 0.084 51 1,579 0.36 1,986 0.35 5 1.13 (1.06,1.20) 0.00017 0.036 56
19 40,960,311 rs12982672 G 1.06 (0.92,1.22) 0.43 0.9 0 2,076 0.92 3,769 0.91 7 1.19 (1.09,1.31) 0.00022 0.49 0
X 56,444,998 rs5913935 G 1.03 (0.92,1.17) 0.58 0.39 4 1,651 0.21 1,985 0.20 5 1.17 (1.08,1.27) 0.00026 0.048 53
c
P values that reach genome-wide significance are bolded
Supplementary table 3 - Association of the top 20 markers from GWA of UBC among 9 follow-up study groups from Europe and among 
the discovery and follow-up groups combined.
FOLLOW-UP COMBINED GWA and FOLLOW UP  COMBINED
a
Phet denotes the tests of heterogeneity performed by comparing the null hypothesis of the effect being the same in all populations to the alternative hypothesis of each 
population having a different effect using a likelihood ratio test.  
b
I
2
 takes values between 0% and 100% and describes the proportion of the total variation in estimates that is due to heterogeneity 
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Marker 1 Marker 2 Location D' R
2
rs798766 rs798727 1654935 0.94732 0.852544
rs798766 rs798726 1655009 0.947917 0.898546
rs798766 rs811316 1659175 1 0.948454
rs798766 rs798719 1667981 1 1
rs798766 rs798756 1677245 1 1
rs798766 rs798741 1682211 1 1
rs798766 rs798744 1684482 1 1
rs798766 rs2236786 1689092 1 1
rs798766 rs798751 1689370 1 1
rs798766 rs798754 1690555 1 1
rs798766 rs798755 1690622 1 1
rs798766 rs3099555 1695449 1 1
rs798766 rs1665364 1697004 1 1
rs798766 rs1665366 1698179 1 0.948454
rs798766 rs798766 1704037 NA NA
rs798766 rs3752749 1707060 1 1
rs798766 rs4865463 1712198 1 1
rs798766 rs2166580 1712967 1 1
rs798766 rs8389 1716642 1 1
rs798766 rs744658 1724872 1 0.861111
rs798766 rs732754 1732085 1 1
Supplementary Table 4. LD between 
rs798766 and 20 HapMap CEU SNPs with 
the strongest correlation in the Icelandic 
and Dutch populations
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 Center OR 95% CI P N Low risk 
cases
Freq N High risk 
cases 
Freq Phet I2
The Netherlands, discovery group 1.27 (1.05-1.54) 0.011 696 0.24 612 0.20
Iceland 1.84 (1.04-3.23) 0.035 119 0.25 58 0.16
Germany 0.87 (0.5-1.52) 0.573 69 0.23 140 0.26
Eastern Europe 1.17 (0.58-2.33) 0.593 38 0.32 99 0.28
Italy, Brescia 1.31 (0.73-2.33) 0.363 45 0.26 113 0.21
Italy, Torino 1.10 (0.69-1.75) 0.638 146 0.25 112 0.23
Spain 1.02 (0.50-2.06) 0.965 28 0.21 137 0.21
Sweden 0.83 (0.57-1.20) 0.293 147 0.23 194 0.26
The United Kingdom 1.22 (0.93-1.61) 0.151 271 0.22 410 0.18
All Combined 1.17 (1.04-1.31) 0.009 1,559 0.25 1,875 0.22 0.35 10
Supplementary table 5 -  Association of rs798766-T with low risk versus high risk tumor characteristics 
among bladder cancer patients from 9 European centers.
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Center N Effect (years) 95%CI Freq P Phet I2
Belgium 183 0.65 (-1.98,3.29) 0.19 0.626
Germany 209 -1.39 (-3.93,1.16) 0.25 0.285
Eastern Europe 209 -1.84 (-4.15,0.48) 0.28 0.120
The Netherlands 1,266 -0.80 (-1.74,0.14) 0.23 0.094
Iceland 612 -1.06 (-2.86,0.75) 0.22 0.251
Italy, Brescia 158 -3.66 (-6.76,-0.56) 0.22 0.021
Italy, Torino 303 -0.97 (-2.39,0.45) 0.24 0.181
Spain 220 -0.66 (-3.51-2.19) 0.23 0.650
Sweden 344 0.57 (-1.47,2.61) 0.25 0.582
The United Kingdom 707 -0.48 (-1.91,0.95) 0.20 0.510
All Combined 4,211 -0.81 (-1.35,-0.26) 0.23 3.60E-03 0.59 0
Supplementary table 6 - Correlation of rs798766-T with age at diagnosis of 
bladder cancer among patients of 10 centers.
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Group rs798766 Hazard Ratio 95% CI P value
Median recurrence-free survival time no yes
All NMIBC Genotype CC vs.CC 1 NA NA 351 289
2.6 years Genotype CT vs. CC 1.198 1.003-1.432 0.046 198 212
Genotype TT vs. CC 1.118 0.753-1.658 0.580 30 27
Allele T vs. C 1.128 0.982-1.296 0.090
Low risk NMIBC Genotype CC vs.CC 1 NA NA 222 169
2.8 years Genotype CT vs. CC 1.309 1.043-1.642 0.020 136 136
Genotype TT vs. CC 1.397 0.848-2.301 0.190 17 17
Allele T vs. C 1.234 1.035-1.471 0.019
High risk NMIBC Genotype CC vs.CC 1 NA NA 125 111
2.3 years Genotype CT vs. CC 1.019 0.745-1.393 0.906 61 63
Genotype TT vs. CC 0.861 0.450-1.644 0.649 12 10
Allele T vs. C 0.971 0.760-1.241 0.816
Supplementary table 7 - Results of Cox proportional hazards regression analysis for risk of 
recurrence.
Recurrence event
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 Supplementary table 8 - Missense mutations in TACC3  and FGFR3 
Pos SNP name Gene Exon aa change P case (n) case (f)a control (n) control (f)a r2 with rs798766 Homozygous 
commonb
Heterozygousb
Homozygous 
rareb
Chr4_1699354 rs34205238 TACC3 4 E143K 0.32 561 0.1631 35,675  0.1748 0.0461 246 83 7
Chr4_1699751 rs17132047 TACC3 4 C275Y 0.57 561 0.2255 35,676  0.2331 0.0662 208 108 21
Chr4_1699786 rs1063743 TACC3 4 G287S 0.59 561 0.2273 35,674  0.2343 0.0667 203 109 22
Chr4_1700177 TACC3 4 P417L 0.14 561 0.0027 35,676  0.0011 0.0003 337 3 0
Chr4_1702776 rs17680881 TACC3 6 G514E 0.52 561 0.2246 35,674  0.2331 0.0663 200 113 23
Chr4_1764874 rs17880408 FGFR3 1 G15R 0.07 561 0.0348 35,667  0.0259 0.0040 317 18 1
Chr4_1764928 FGFR3 1 A33T 0.33 561 0.0053 35,667  0.0038 0.0008 336 4 0
Chr4_1772970 FGFR3 5 R175H 0.06 561 0.0027 35,684  0.0079 0.0017 350 3 0
Chr4_1776427 FGFR3 10 P449S 1.00 561 0.0009 35,684  0.0017 0.0004 340 4 0
Chr4_1778684 FGFR3 18 G661D 0.86 561 0.0080 35,684  0.0078 0.0017 344 7 0
a Frequency estimated from the imputed data 
b Genotype counts observed among sequenced individuals
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Probe Transcript Chr Start End
NM_052861 MGC21675 chr4 1236201 1236261
NM_005882 MAEA chr4 1323819 1323878
NM_175918 FLJ34443 chr4 1379707 1379767
NM_006527 SLBP chr4 1664454 1664514
NM_138385 TMEM129 chr4 1687477 1687537
NM_006342 TACC3 chr4 1716581 1716641
NM_000142 FGFR3 chr4 1780330 1780390
NM_012318 LETM1 chr4 1784579 1784640
NM_133334 WHSC1 chr4 1920283 1920343
NM_005663 WHSC2 chr4 1954250 1954310
Contig22095_RC WHSC2 chr4 2008040 2008100
ENST00000290995 (null) chr4 2012859 2012919
NM_178557 FLJ37478 chr4 2037373 2037433
NM_181808 POLN chr4 2043558 2043618
NM_024511 C4orf15 chr4 2203369 2203429
Supplementary table 9 - Transcripts located in a 1 MB region 
centered on rs798766 on chr4p16.3
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Gene (Transcript) Tissue Effect P P adj SNP (r 2) P P adj
FGFR3  (NM_000142) Adipose 22.40% 8.9×10-16 rs798766
TACC3  (NM_006342) Adipose 9.10% 1.8×10-26 0.48 rs2236786 (1.00) 7.2×10-29 0.0022
TACC3  (NM_006342) Blood 7.80% 1.0×10-11 0.007 rs2854915 (0.16) 2.8×10-32 1.3×10-22
TMEM129 (NM_138385) Adipose 3.60% 5.5×10-6 0.0054 rs1374468 (0.03) 4.3×10-27 9.3×10-24
Best cis SNP
The table includes the correlation between the UBC risk variant rs798766-T and the expression levels of transcripts measured in 
adipose tissue from 606 individuals and in whole blood from 747 individuals. The correlation is tested for 15 transcript located in a 
1 Mb window centred on rs798766 by regressing the MLR values (the mean log10 expression ratio) on the number of copies of 
rs798766[T] an individual carries. The effect of age and sex (and differential cell count for whole blood) is taken into account by 
including the corresponding terms in the regression analysis. The table includes the gene and the transcript tested, the tissue, the 
effected measure as percentage change in the relative expression, and the P value. Only correlation tests with P < 0.001 are 
included. For each transcript the table also includes the variant, out of 449 tested variants in the 1 Mb region, that shows the most 
significant correlation with the expression (cisSNP), the correlation (r2) between that cisSNP and rs798766, and adjusted P values 
when the correlation with rs798766 is conditional on the cisSNP and vice verse. All P values have been adjusted for relatedness of 
the individual by the method of genomic control.
Supplementary table 10 - Correlation between rs798766-T and expression of nearby 
transcripts.
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Patient Stage Grade rs798766 FGFR3 mutation
1 pTa 1 CC WT
2 pTa 1 CC WT
3 pTa 2 CC S249C
4 pTa 2 CC S249C
5 pTa 2 CC Y375C
6 pTa 2 CC S249C
7 pTa 2 CC S249C
8 pTa 2 CC WT
9 pTa 2 CC G372C
10 pTa 2 CC WT
11 pTa 2 CC S249C
12 pTa 2 CC K652E
13 pTa 2 CC S249C
14 pTa 2 CC S249C
15 pTa 2 CC G372C
16 pTa 2 CC G372C
17 pTa 2 CC S249C
18 pTa 2 CC WT
19 pTa 2 CC R248C
20 pTa 2 CC S249C
21 pTa 2 CC WT
22 pTa 2 CC S249C 
23 pTa 2 CC S249C 
24 pTa 2 CC S249C
25 pTa 2 CC S249C
26 pTa 2 CC WT
27 pTa 2 CC WT
28 pTa 2 CC S249C
29 pTa 2 CC WT
30 pTa 2 CC WT
31 pTa 2 CC S249C
32 pTa 2 CC WT
33 pTa 3 CC WT
34 pTa 3 CC WT
35 pTa 3 CC WT
36 pTa 3 CC WT
37 pTa 3 CC WT
38 pTa 3 CC WT
39 pTa 3 CC WT
40 pTa 3 CC WT
41 pTa 3 CC S249C 
42 pTa 3 CC WT
43 pTa 1 CC S249C
44 pTa 1 CC S249C
45 pTa 1 CC WT 
Supplementary table 11 - Characteristics of tumors used 
for somatic mutation analysis.
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46 pTa 1 CC WT
47 pTa 1 CC WT
48 pTa 1 CC S249C
49 pTa 1 CC WT
50 pTa 1 CC R248C
51 pTa 2 CC WT
52 pTa 1 CT S249C
53 pTa 2 CT WT
54 pTa 2 CT S249C
55 pTa 2 CT S249C
56 pTa 2 CT WT
57 pTa 2 CT WT
58 pTa 2 CT S249C
59 pTa 2 CT S249C 
60 pTa 2 CT WT
61 pTa 2 CT S249C
62 pTa 2 CT S249C 
63 pTa 2 CT Y375C
64 pTa 2 CT WT
65 pTa 2 CT WT
66 pTa 2 CT S249C
67 pTa 2 CT S249C
68 pTa 2 CT S249C
69 pTa 2 CT S249C
70 pTa 2 CT S249C
71 pTa 2 CT Y375C
72 pTa 2 CT S249C
73 pTa 2 CT S249C
74 pTa 2 CT S249C
75 pTa 3 CT S249C
76 pTa 3 CT S249C
77 pTa 3 CT Y375C
78 pTa 3 CT Y375C
79 pTa 3 CT S249C
80 pTa 3 CT R248C 
81 pTa 1 CT G372C
82 pTa 1 CT S249C
83 pTa 1 CT WT
84 pTa 2 CT S373C
85 pTa 2 CT R248C
86 pTa 1 TT S249C
87 pTa 2 TT WT
88 pTa 2 TT S249C
89 pTa 1 TT S249C
90 pTa 2 TT S249C
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 Supplementary Table 12 - Primers and probes used for FGFR3 mutation 
analysis 
    Primers 
   
    Exon Forward primer Reverse primer 
 7 5′-AGTGGCGGTGGTGGTGAGGGAG-3′  5′-GCACCGCCGTCTGGTTGG-3′ 
 10 5′-CAACGCCCATGTCTTTGCAG-3′  5′-AGGCGGCAGAGCGTCACAG-3′; 
 15 5′-GACCGAGGACAACGTGATG-3′  5′-GTGTGGGAAGGCGGTGTTG-3′ 
 
    
    Probes 
   
    Name Probe sequence 
  R248C T46    CGT CAT CTG CCC CCA CAG AG 
  S249C T36    TCT GCC CCC ACA GAG CGC T 
  G372C T29    GGT GGA GGC TGA CGA GGC G 
  Y375C T43    ACG AGG CGG GCA GTG TGT 
  A393E T34    CCT GTT CAT CCT GGT GGT GG 
  K652M/T T20    CAC AAC CTC GAC TAC TAC AAG A 
  K652E/Q T50    GCA CAA CCT CGA CTA CTA CAA G 
  S373C T19    GAG GAT GCC TGC ATA CAC AC 
  G382R T56    GAA CAG GAA GAA GCC CAC CC 
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 (a) Log-rank test: p=0.044 
 
 
 
(b) Log rank test: p=0.882  
 
Supplementary Figure 1.  Risk of recurrence of UBC by rs798766 genotype among patients with non-
muscle invasive bladder cancer, stratified by predicted (a) low or (b) high risk of progression at diagnosis. 
Blue line represents rs798766-CC; green line represents rs798766-CT, beige line represents rs798766-TT.  
The corresponding recurrence event counts are displayed in the tables below. 
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rs798766 genotype and recurrence for patients 
 with low predicted risk of progression 
 
  Recurrence event 
Total   0 (=no) 1 (=yes) 
rs798766 CC 222 169 391 
CT 
TT 
136 
17 
136 
17 
272 
34 
Total 375 322 697 
 
rs798766 genotype and recurrence for patients  
with high predicted risk of progression 
 
  Recurrence event 
Total   0 (=no) 1 (=yes) 
rs798766 CC 125 111 236 
CT 
TT 
61 
12 
63 
10 
124 
22 
Total 198 184 382 
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